acelyrin.com (SLRN): Net earnings per share growth forecast for next year

ACELYRIN, Inc. - graphic logo of issuer SLRN

Acelyrin, Inc. (SLRN) develops penetrating proteins to combat deep foci of skin inflammation. A forward-looking assessment of net profit dynamics demonstrates market expectations, where 0.00 determines this parameter level. The company aims to bring convenient arthritis medications to market, yet it is currently forced to cut costs and optimize its research program to survive in a competitive environment.

SLRN: Acelyrin Inc. Earnings growth forecast for next year 02/21/2024 - 05/31/2025

Metric breakdowns and analytics for acelyrin.com (SLRN)

- share price and consensus valuation forecast:
Stock Price ACELYRIN, Inc.|SLRN - Average Forecast Price
- stock exchange capitalization data:
Market Value ACELYRIN|SLRN - Value Adjusted for Debt and Cash
- company book value details:
Book Value per Share ACELYRIN|SLRN - Book Capitalization|Market Capitalization to Book Value Ratio acelyrin.com|SLRN - Cumulative Company Assets
- company total debt and liquidity indicators:
Total Debt to Capital Acelyrin, Inc.|SLRN - Long-Term Liabilities to Capital|Short-Term Debt to Equity ACELYRIN|SLRN - Company Debts|Debt to Book Value ACELYRIN|SLRN - Long-Term Debt|Company Short-Term Debt ACELYRIN|Quick Ratio acelyrin.com
- earnings and valuation multiples information:
SLRN - Net Financial Result|Expected Profit Acelyrin, Inc.|SLRN - Price to Earnings Multiple|Projected Price to Earnings Acelyrin, Inc.|SLRN - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple ACELYRIN|SLRN - Operating income before deduction of amortization|Earnings per share for the last twelve months ACELYRIN|SLRN - Earnings per share for the last 12 months|Quarterly EPS earnings growth acelyrin.com|SLRN - Net earnings per share growth this year|Expected earnings per share growth for next year Acelyrin, Inc.
Summary company analysis:ACELYRIN, Inc.
Finished products of ACELYRIN

This indicator measures the expected earnings per share (EPS) growth for the coming year, reflecting the market consensus regarding future profitability and the issuer's ability to generate cash flow. By analyzing the forward net income trend, an investor can assess the resilience of Acelyrin, Inc. (SLRN) as a defensive asset, whose unique medical developments create stable demand independent of global macroeconomic fluctuations.

Competitors of Acelyrin, Inc.

HLN (Haleon Group) - Earnings growth forecast for next year|Expected net earnings per share growth next year Kenvue Health KVUE|Net earnings per share growth forecast for next year Verona Pharma plc (VRNA)|MENS (jyongbio.com) - Expected earnings per share trend next year|Earnings growth forecast for next year LGND (Ligand)|Earnings growth forecast for next year Amneal Pharmaceuticals, Inc. AMRX|Perrigo Company - Earnings growth forecast for next year|Alvotech Biopharmaceuticals (ALVO) - Expected earnings per share growth for next year|LQDA: Earnings growth forecast for next year|Expected net earnings per share growth next year glpg.com (GLPG)|Net earnings per share growth forecast for next year ANI Pharmaceuticals, Inc.|Net earnings per share growth forecast for next year MNKD|Expected earnings per share growth for next year AMPH (Amphastar)|PCRX - Expected net earnings per share growth next year|Net earnings per share growth forecast for next year ARS Pharmaceuticals SPRY|Expected earnings per share trend next year TBPH|Aquestive Therapeutics, Inc. - Earnings growth forecast for next year|Consensus forecast of earnings per share growth for next year scPharmaceuticals Inc. SCPH|tectonictx.com (TECX) - Net earnings per share growth forecast for next year|Projected earnings per share growth rate for next year TNXP|Expected earnings per share growth for next year SXTC|EPRX: Expected earnings per share trend next year|Earnings growth forecast for next year BHST|Consensus forecast of earnings per share growth for next year Invizyne Technologies|Net earnings per share growth forecast for next year Oramed Pharmaceuticals Inc. ORMP|ENTX: Projected earnings per share growth rate for next year|MindWalk Holdings - Earnings growth forecast for next year|abvcpharma.com (ABVC) - Expected earnings per share growth for next year|CPIX (Cumberland Pharmaceuticals Inc.) - Expected earnings per share growth for next year|QNTM - Consensus forecast of earnings per share growth for next year|Net earnings per share growth forecast for next year FibroGen Corp|Telomir Pharmaceuticals Corp (TELO) - Consensus forecast of earnings per share growth for next year|Net earnings per share growth forecast for next year Rani Therapeutics (RANI)|Net earnings per share growth forecast for next year SNYR (synergychc.com)|Net earnings per share growth forecast for next year Rallybio RLYB|Expected earnings per share trend next year LEXX|PULM - Net earnings per share growth forecast for next year|PTHL (Pheton Holdings Ltd) - Projected earnings per share growth rate for next year|aptorumgroup.com (APM) - Net earnings per share growth forecast for next year|Net earnings per share change forecast for next year LYRA (lyratherapeutics.com)|IBO (Impact BioMedical Inc) - Earnings growth forecast for next year|TNFA: Expected earnings per share trend next year|Earnings growth forecast for next year YCBD|Earnings growth forecast for next year PainReform Corp (PRFX)|Net earnings per share growth forecast for next year Altamira Therapeutics Ltd. CYTO|Expected earnings per share trend next year LIPO|OPTN - Net earnings per share growth forecast for next year|Pieris Pharmaceuticals Inc (PIRS) - Expected earnings per share growth for next year|PROC: Earnings growth forecast for next year|Petros Pharma (PTPI) - Earnings growth forecast for next year|Expected earnings per share growth for next year QLI|TFFP: Expected earnings per share trend next year